TRVN


Trevena, Inc. Stock Soars as Analysts Cheer Phase 2b Results for TRV130

Biotechnology company Trevena, Inc. (NASDAQ:TRVN) discovers and develops therapeutics to target G protein coupled receptors, or GPCRs.

Weekend Ideas and Market Takes Report: Biotechnology Sector

Quick SPDR S&P 500 ETF Trust (NYSE ARCA:SPY) forecast update:  Back on November 10th 2014 we predicted a spring 2015 high of 2181 …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts